TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient receiving hemodialysis at a DaVita clinic/dialysis center~* Receiving in-center hemodialysis thrice weekly~* Central venous catheter (CVC) use for \> 180 days~* Patients report a fear of needles as a top-3-reason for failure to get an arteriovenous fistula/graft~Exclusion Criteria:~* Patients have a known intolerance or hypersensitivity to Synera~* Patient with a history of or past diagnosis of severe hepatic disease~* Patient is currently receiving any class 1 antiarrhythmic drugs (i.e., tocainide, mexiletine, etc)~* Patient has a clinically significant illness within 14 days of Screening/Day 1 that, in the opinion of the investigator, would preclude the subject from participating in the study~* Patient has an AVF or AVG in place or is scheduled for placement~* Women and men whose partners are of childbearing potential (defined as premenopausal and not surgically sterilized \[ie, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy\] or postmenopausal for \< 2 years) agree to practice 1 of the following medically acceptable methods of birth control and agree to continue with the regimen throughout the duration of the study: Oral, implantable, or injectable contraceptives for 3 consecutive months before the Screening Visit; Intrauterine device (IUD); and double barrier method (ie, condom, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)~* Patient has significant disease or condition that, in the PI's opinion, may interfere with protocol adherence or subjects' ability to provide informed consent~* Patient is unable to read or comprehend English at a 6th grade level~* Patient has a visual impairment and is unable to read the survey instruments~* Patient has a suspected or known access-related infection at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced Needle Phobia Intervention (Type: EXPERIMENTAL): Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
- Standard Needle Phobia Intervention (Type: ACTIVE_COMPARATOR): Patients will receive the standard intervention for needle phobia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants ≥ 40 years of age at baseline visit~* Patients with confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Patients who have been on Spiriva® HandiHaler® for ≥ 6 weeks at baseline visit~* Patients for whom a switch from Spiriva® HandiHaler® to Spiriva® Respimat® was planned prior to study inclusion. If additional inhalative COPD drugs (AICDs) are used: AICD treatment must have been stable for at least 6 weeks before study inclusion~* Signed written informed consent form to participation~Exclusion Criteria:~* Patients who have contraindications to Spiriva® Respimat® according to the current prescribing information label/ summary of product characteristics (SmPC)~* Patients who have signs of a current, acute respiratory tract infection 2 weeks prior visit 1~* Patients for whom further follow-up will not be possible at the enrolling site during the planned observational period (of approximately 8 weeks)~* Patients with confirmed diagnosis of only asthma~* Patients who had \> 1 moderate to severe exacerbation(s) within the last 6 weeks prior to study inclusion~* Patients who are pregnant or breastfeeding~* Patients participating in an ongoing interventional study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients switching from Spiriva® HandiHaler® to Spiriva® Respimat® (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 to 80~2. Skin and soft tissue infections (SSTIs), in the form of an abscess, which will require incision and drainage.~3. Patient able to provide an informed consent.~4. Patient volunteers to participate.~Exclusion Criteria:~1. Wound was caused by human or animal bite.~2. Wound is a blunt crush injury or has tendon, bone, or joint involvement.~3. Diabetic foot infection.~4. Anticipated incision size less than 5mm.~5. Abscess extends to the muscle layer.~6. Admission to hospital for any reason, including IV antibiotics.~7. Clinical signs of systemic infection on initial patient encounter.~8. Prior history of allergy or hypersensitivity to CHG.~9. Neutropenic (known ANC\<500/mm3), HIV (known CD4\<50), or other severely immunocompromised state (e.g., receiving chemotherapy).~10. Patient is diagnosed with systemic lupus erythematosus or other immunological disease.~11. Currently in police custody.~12. Patient withdraws from participation.~13. Patient unable or unwilling to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SoC) (Type: ACTIVE_COMPARATOR): For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
- Irrisept (Type: ACTIVE_COMPARATOR): For subjects randomized to the investigational group, Irrisept was used.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HIV Pre-Exposure Prophylaxis Among an Unrecognized Sexual Minority Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~In order to be eligible to participate in this study, an individual must meet all of the following criteria:~* Successful completion of screening checklist to indicate one of the following conditions:~  o currently engaging, or have engaged in the last 3 months, in consensual kink activities such as power exchange (Dominant/submissive roles), bondage, sadomasochism, or fetish activities. By fetish, we mean a type of sexual desire in which gratification depends on or is significantly increased by particular objects, clothing items, parts of the body, or types of persons.~* Successful completion of screening checklist to indicate the following conditions:~  * weigh at least 35 kg;~ * report negative HIV serostatus, OR report that they don't know their HIV serostatus;~ * has never taken PrEP or been involved in any investigation trial of PrEP medication~* Age of majority in the legal jurisdiction (geographic location) where the survey is taken (usually age 18)~* English-language proficiency sufficient to understand the study instruments~* Completion of an electronically signed and dated informed consent form~Exclusion Criteria:~Individuals will be ineligible for participation if they:~* Are younger than 18 years of age~* Weigh less than 35 kg~* Are currently on PrEP~* Enrolled in an investigational trial of PrEP medication~* Have a self-reported positive HIV serostatus~* Have previously used PrEP but was required to discontinue use due to serious side effects or medical contraindications~* Have been diagnosed with renal failure or are dialysis dependent~* Are currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): experimental group, receiving 3 exposures to the kink-focused video intervention
- Group B (Type: OTHER): control group, receiving no exposure to the kink-focused video, but seeing the generic / standard video
- Group C (Type: OTHER): group that receives 1 exposure to the generic / standard video, and later 2 exposures to the kink-focused video
- Group D (Type: OTHER): group that receives 2 exposures to the generic / standard video, and later 1 exposure to the kink-focused video

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topical Garlic Concentrate for Alopecia Areata in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 4 years and older up to 18 years of age~* Patches of alopecia areata that affect less than 50% of the scalp.~* Alopecia of at least 1 year duration without evidence of regrowth~* Informed written consent~Exclusion Criteria:~* Any children experiencing significant spontaneous regrowth of terminal hair at the baseline visit.~* Any children treated with a topical, (including shampoos with active ingredients like minoxidil or clobetasol), intralesional or systemic agent likely to cause regrowth in alopecia areata within the past month from the baseline visit and during study period.~* Children with history of hypersensitivity to garlic.~* Children with widespread alopecia areata as alopecia totalis, universalis, ophiasis or diffuse Alopecia Areata.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Garlic concentrate (Type: EXPERIMENTAL): Garlic gel concentrate- once a day topical application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female; ages 18 to 80 years old~2. Receiving treatment at Cancer Treatment Centers of America~3. Receiving PN (either in the infusion center or at home)~4. Have existing hepatic dysfunction defined as Elevation of \> 3x the normal level of one or more of the following:Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), or Alanine Aminotransferase ALT) and/or Bilirubin \> 2 mg/dl in the absence of biliary obstruction~5. Able to provide informed written consent~Exclusion Criteria:~1. Hypertriglyceridemia (triglycerides \[TG\] \> 400)~2. Allergy to fish or egg protein~3. Currently on therapeutic doses of Coumadin, heparin, or low molecular eight heparin~4. Hemodynamically unstable~5. Bilirubin \> 5 mg/dL~6. Documented liver metastases~7. Unstable diabetes with known diabetic ketoacidosis within 7 days of screening~8. Recent cardiac infarction (within 6 months) and taking plavix~9. Severe hemorrhagic disorders~10. Current anticoagulation therapy for deep venous thromboembolism or pulmonary embolism~11. Active sepsis~12. Undefined coma status~13. In patients with abnormal kidney function, renal insufficiency with calculated creatinine clearance \< 30 mL/min~14. Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Omegaven (compassionate use) (Type: EXPERIMENTAL): This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The participant is a male or female child aged ≥7 and \<12 years or adolescent aged ≥12 and ≤18 years in the lead-in study (12709A and 12710A).~* The participant must have completed Study 12709A or 12710A (Visit 12, Completion Visit) immediately prior to enrolment into this extension study.~* The participant had a primary diagnosis of MDD at entry in study 12709A or 12710A, diagnosed according to DSM-5™.~* The participant is indicated for long-term treatment with vortioxetine according to the clinical opinion of the Investigator.~* For participants aged ≥7 and ≤17 years at the Baseline visit; the participant is able to understand the Informed Assent Form, and parent(s)/legal representative(s) are able to read and understand the Informed Consent Form.~* For participants who turned 18 years during the lead-in study 12710A; the participant has signed the Informed Consent Form.~Exclusion Criteria:~* The participant has been diagnosed with another psychiatric disorder (for example mania, bipolar disorder, schizophrenia or any psychotic disorder) during study 12709A or 12710A.~* The participant has an attention-deficit/hyperactivity disorder (ADHD) that requires a pharmacological treatment other than a stimulant medication.~Other protocol-defined inclusion and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): Vortioxetine tablets for 26 weeks. Single dose of vortioxetine oral drops (only a subset of participants).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements~* Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale~* Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.~Exclusion Criteria:~* Refusal to give informed consent~* A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.~* Current post-traumatic seizure disorder~* A previous diagnosis of a psychotic disorder~* Current or previous (in the last 6 months) treatment history for alcohol or substance dependency~* Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.~* A known suicide risk~* A pregnant or breastfeeding woman~* Uncontrolled narrow-angle glaucoma~* Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study~* Liver enzymes \> 1.5 times upper limit of normal~* Patients with end-stage renal disease (requiring dialysis) or severe renal impairment~* Known hypersensitivity to duloxetine or any of the inactive ingredients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: ACTIVE_COMPARATOR): Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
- Sugar pill (Type: PLACEBO_COMPARATOR): Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicentric Study Comparing the Acute Hemodynamic Effect of Three Modes of Stimulation in Cardiac Resynchronization Therapy Recipients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18~* Implantation of a CRT (CRT-P or CRT-D) less than 3 months before inclusion~* MPP and SyncAV-enabled ABBOTT Quadripolar CRT pacing system~* Patient who had signed an informed consent and is willing to comply with study requirements~* De novo implantation~* Patient covered by national healthcare insurance~Exclusion Criteria:~* Permanent/persistant atrial fibrillation/ supra-ventricular tachycardia~* Pacing indication for 2nd or 3rd degree AV block~* Upgrading from non-CRT system~* Pregnant or breastfeeding women~* Adult under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT device (Type: EXPERIMENTAL): Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of intrinsic pontine brain stem glioma within the past 30 days~  * Histologic confirmation not required provided the tumor has a pontine epicenter AND exhibits diffuse (rather than focal) involvement of ≥ 2/3 of the pons with or without extension to the adjacent medulla or midbrain\* NOTE: \*Brain stem tumors that do not meet these criteria must be histologically confirmed as grade III or IV malignant glioma~* Measurable disease by radiographic imaging~  * Post-operative MRI required within the past 30 days if patient had a biopsy or surgical resection~* No disseminated disease~* No neurofibromatosis type 1~PATIENT CHARACTERISTICS:~Age~* 3 to 21 at diagnosis~Performance status~* Lansky 50-100% OR~* Karnofsky 50-100%~Life expectancy~* At least 8 weeks~Hematopoietic~* Absolute neutrophil count ≥ 1,000/mm\^3~* Platelet count ≥ 100,000/mm\^3 (transfusion independent)~* Hemoglobin ≥ 10.0 g/dL (transfusion allowed)~Hepatic~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT \< 2.5 times ULN~Renal~* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min OR~* Creatinine based on age as follows:~  * No greater than 0.8 mg/dL (for patients ≤ 5 years of age)~ * No greater than 1.0 mg/dL (for patients 6 to 10 years of age)~ * No greater than 1.2 mg/dL (for patients 11 to 15 years of age)~ * No greater than 1.5 mg/dL (for patients over 15 years of age)~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Not severely somnolent or comatose~  * Central cortical neurotoxicity scale \< grade 3~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunomodulating agents~Chemotherapy~* No other concurrent anticancer chemotherapy~Endocrine therapy~* Concurrent corticosteroids allowed for neurological deficits related to the tumor~Radiotherapy~* No prior radiotherapy~Surgery~* See Disease Characteristics~* Prior biopsy or surgical resection for malignant brain stem glioma allowed~Other~* No other prior therapy for malignant brain stem glioma

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Dose Level I (0.5 mg/m^2) (Type: EXPERIMENTAL): Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
- Dose Level 2 (0.6 mg/m^2) (Type: EXPERIMENTAL): Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy